Refine by
Vaccine Based Articles & Analysis
86 news found
This strategic move is aimed at addressing the rising global demand for Lipid Nanoparticles (LNPs), which are vital for nucleic acid drug delivery, especially in mRNA-based therapies and vaccines. Lipid Nanoparticles have become a groundbreaking delivery mechanism within the biopharmaceutical sector. ...
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. Oncovita and the Institut Pasteur have already been working together for ...
ByOncoVITA
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its comprehensive portfolio of ELISA Based Assays for vaccine development and bioprocess applications. Vaccine development involves a variety of assays to support vaccine research and ...
“I am excited to announce this development and commercialization agreement to explore the potential to utilize our C1 protein production platform to produce high-quality messenger RNA products at lower cost which will be easier to manufacture than in vitro mRNA, making it accessible to everyone, including patients from poorer countries. The global mRNA vaccine and ...
In addition, these new reagents can be applied in various fields, such as mRNA-base vaccine therapy for malignant tumors, protein replacement therapy, and gene editing using mRNA recombination technology. mRNA vaccines protect against infectious diseases like influenza, rabies, HIV and Zika virus infections. ...
Challenges in viral vaccine manufacturing: “The product is the process” In the vaccine field, “the product is the process”. ...
ByNuvonis
CEPI will provide seed funding of up to US$4.8m to NEC OncoImmunity AS (NOI), a Norway-based subsidiary of NEC, which specializes in artificial intelligence-driven biotechnology, to support the initial development of broadly protective betacoronavirus vaccine candidates. NEC, through NOI, will lead a research consortium including the European ...
“Emergent is pleased to gain the support of the CDMRP to verify the clinical benefit of our CHIKV VLP vaccine candidate for CHIKV disease through a post-approval field efficacy study,” said Chris Cabell, M.D., chief medical officer and SVP clinical development at Emergent BioSolutions. ...
Mariola Fotin-Mleczek, PhD, has over 20 years of experience in developing and optimizing the broad spectrum of therapeuticals mainly based on messenger RNA (mRNA) for medical purposes. She has co-authored over 30 scientific publications with the main focus on the multiple patented mRNA-based therapies (mainly vaccines). ...
ByArdigen
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. According to the official speaker from Creative BioMart, based on ...
ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the Vaccines Summit 2022 in Washington DC on October 11-13. Founder of ImmunAdd, Pi-Hui Liang, said “My team and I were delighted to attend the Vaccines Summit, an ...
The sublingual COVID-19 vaccine uses sublingual mucosal delivery technology to deliver the vaccine to the mucous membrane. ...
It is hoped that this will form the basis for developing products to improve the surveillance of active and emerging viruses, provide an off the shelf solution for the non-cryo distribution of viral vectors, and even increase the equitable access of RNA-based vaccines through removing the need for ultra-low temperature shipment. ...
CD BioGlyco, a biotechnology company specialized in the field of glycobiology, has developed a series of advanced vaccine development platforms by integrating various advanced technologies to promote the development of glycol-based vaccines. ...
ImmunAdd’s next-generation Saponin-based adjuvant IA-05 induced both humoral and cellular immunities in various vaccines, including those against COVID-19, influenza, and cancer. ...
Approved Quotes “We are proud to work with Ziphius Vaccines in their early-stage program. The advancement of saRNA technologies is an exciting avenue for the development of vaccines and therapeutic programs, and we’re looking forward to a successful ...
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, and University of Antwerp today announce that they have entered into a collaboration agreement to research and develop a ...
(Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. ...
ByVaxxinit
The company is pioneering a new class of synthetic, peptide-based immunotherapeutic vaccines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of ...
ByVaxxinit
The company is pioneering a new class of synthetic, peptide-based immunotherapeutic vaccines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of ...
ByVaxxinit